Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Testing The Limits? FDA Drugs Of Abuse Guidance Draws Mixed Reaction

This article was originally published in The Gray Sheet

Executive Summary

On-site testing manufacturers once again are questioning FDA's regulatory authority regarding on-site drugs of abuse tests intended for non-medical purposes
Advertisement

Related Content

Drug Abuse Test Manufacturers May Benefit From Revised Federal Standards
Drug Abuse Test Manufacturers May Benefit From Revised Federal Standards
Warning Letter To Alcohol Test Manufacturer Cites Purchasing Control Lapses
Warning Letter To Alcohol Test Manufacturer Cites Purchasing Control Lapses
Flexible Approach Granted For Drugs-Of-Abuse Premarket Submissions
FDA Lacks Authority to Regulate Drug Abuse Tests in Workplace - NOTA
FDA Lacks Authority to Regulate Drug Abuse Tests in Workplace - NOTA
Advertisement
UsernamePublicRestriction

Register

MT019960

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel